semaglutide cardiovascular trial news Semaglutide improves cardiovascular outcomes - New oralsemaglutide once-weekly semaglutide was associated with a 25% risk reduction of heart attack Semaglutide Cardiovascular Trial News: A Groundbreaking Advancement in Heart Health

New oralsemaglutide Recent semaglutide cardiovascular trial news has illuminated a significant advancement in the fight against cardiovascular disease, particularly for individuals struggling with overweight or obesity.Semaglutide protects the heart beyond weight loss ... Emerging research indicates that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, not only aids in weight management but also demonstrates a remarkable ability to reduce major adverse cardiovascular events (MACE). This groundbreaking discovery is reshaping our understanding of how metabolic health and cardiovascular well-being are intrinsically linked, offering new hope and treatment avenues for millions.

The pivotal SELECT trial has been a cornerstone in this evolving narrative. Published data from the SELECT trial revealed that semaglutide demonstrated a significant reduction in MACE among patients who were overweight or obese, even in the absence of diabetes.Semaglutide may provide early protection against heart ... This finding challenges previous assumptions, suggesting that the cardiovascular benefits of semaglutide may extend beyond its glycemic control effects. Further analysis of the SELECT trial data found that semaglutide reduced the risk of major adverse cardiac events by 20%作者：N Krüger·2025·被引用次数：1—Here we conducted five cohort studies to assess the effectiveness of tirzepatide andsemaglutidein patients with elevatedcardiovascularrisk, .... This impressive figure underscores the drug's potent cardioprotective capabilities. Importantly, this risk reduction was observed across various body weight and waist circumference levels, indicating that semaglutide lowered the risk of major adverse cardiovascular events irrespective of the degree of weight loss achievedSemaglutide Effects on Cardiovascular Outcomes in .... This has led to expert reactions, with some highlighting that the anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight individuals lose.

The significance of these findings is further amplified by the approval of oral semaglutide. In October 2025, regulatory bodies approved oral semaglutide (R1 formulation) for the reduction of MACE in adults. The SOUL study, a crucial trial, demonstrated that oral semaglutide achieved its primary endpoint, showing a 14% reduction in the risk of MACE in adults. Subsequent findings from the SOUL study further highlighted that oral semaglutide significantly reduces cardiovascular risk in patients with type 2 diabetes, even when they are on concurrent SGLT2 inhibitor therapyOral semaglutide reduces risk of cardiovascular events. Moreover, the SOUL trial also showed that oral semaglutide improved each of the composite measures, which included death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction2025年10月26日—Semaglutide lowered the risk of major adverse cardiovascular eventsacross all body weight and waist circumference levels in people with .... Another key study, the REACH study, demonstrated that once-weekly semaglutide was associated with a 25% risk reduction of heart attack and stroke.

Beyond its impact on individuals with diabetes, semaglutide also shows considerable promise for those without the conditionSemaglutide Effects on Cardiovascular Outcomes in .... The SELECT trial specifically investigated semaglutide cardiovascular risk reduction in non-diabetics taking semaglutide, confirming its benefits in this population2025年6月23日—Oral semaglutide improved each of the composite measures, death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction.. Research indicates that improved cardiovascular outcomes are associated with semaglutide therapy in patients with overweight or obesity who do not have diabetes作者：J Deanfield·2025·被引用次数：18—The SELECT trial foundsemaglutide reduced major adverse cardiovascular events(MACE) in patients with overweight or obesity with .... This is particularly noteworthy as Wegovy (a brand name for semaglutide) is now recognized as the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease.Oral semaglutide reduces cardiovascular event rates in ...

Comparisons between semaglutide and other emerging treatments are also a significant area of focus in the current semaglutide cardiovascular trial news. Studies assessing the cardiovascular outcomes of semaglutide and tirzepatide have provided valuable insightsSOUL trial shows oral semaglutide has positive CV .... In some real-world data involving 800,000 patients, semaglutide and tirzepatide showed comparable cardiovascular protection. However, other analyses suggest that semaglutide may be superior to tirzepatide in reducing MACE risk for patients with overweight/obesity and established cardiovascular disease (CVD)Study Finds Oral Semaglutide Vastly Reduces Heart ....

The scientific community is actively exploring the mechanisms behind these cardiovascular benefits. Emerging evidence suggests that semaglutide protects the heart beyond weight loss, implying that its effects might be multifactorial, potentially influencing inflammatory pathways or directly impacting cardiac function. The precise ways in which semaglutide contributes to cardiovascular health are continuously being investigated, with research exploring its role in protecting against heart damage. For instance, in patients who experienced an early cardiovascular event, those taking semaglutide had approximately 40% fewer major events at 3 and 6 months.Semaglutide and Cardiovascular Outcomes in Obesity ...

Overall, the semaglutide cardiovascular trial news presents a compelling case for the drug's vital role in modern cardiovascular medicine. From reducing the risk of major adverse cardiovascular events to offering protection regardless of weight loss, and even demonstrating potential early protection against heart issues, semaglutide is proving to be a transformative therapy. The ongoing research, including studies on new oral semaglutide formulations and their efficacy in specific patient groups like those with type 2 diabetes, promises to further solidify semaglutide's position as a critical tool in managing cardiovascular healthSemaglutide Superior to Tirzepatide in Reducing .... Experts believe that semaglutide (Wegovy), an anti-obesity medication, could help lower cardiac risk, marking a significant paradigm shift in how we approach obesity and its associated cardiovascular sequelae. The consistent findings across multiple trials, including the SELECT trial and the SOUL trial, reinforce the conclusion that semaglutide improves cardiovascular outcomes and semaglutide reduced cardiovascular events substantially, offering a brighter future for individuals at high cardiovascular risk.